Accession Number:

ADA443979

Title:

Cyclin E, a Powerful Predictor of Survival in Breast Cancer-A Prospective Study

Descriptive Note:

Annual rept. 1 Jun 2003-31 May 2004

Corporate Author:

M D ANDERSON CANCER CENTER HOUSTON TX

Personal Author(s):

Report Date:

2004-06-01

Pagination or Media Count:

13.0

Abstract:

Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death regardless of whether patients had lymph node-negative disease or lymph node-positive disease p 0.0001. Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will 1 use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2 examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3 develop an immunohistochemical I HO assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases

Subject Categories:

  • Biochemistry
  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE